19 results on '"Elvira Umyarova"'
Search Results
2. Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
- Author
-
Abdullah M. Khan, Michael Ozga, Harshil Bhatt, Muhammad S. Faisal, Sadia Ansari, Qiuhong Zhao, Naresh Bumma, Francesca Cottini, Srinivas Devarakonda, Ashley Rosko, Nidhi Sharma, Elvira Umyarova, and Don Benson
- Subjects
Cancer Research ,Oncology ,Hematology - Abstract
The role of salvage autologous hematopoietic cell transplantation (sAHCT2) for patients with relapsed/refractory multiple myeloma (RRMM) in the era of modern therapeutics is unclear. As prospective data is limited, we conducted a retrospective analysis to determine the outcomes of sAHCT2.We conducted a single-institution, retrospective analysis of patients who received sAHCT2 at The Ohio State University from 2000 to 2018. Patients who received a second transplant as part of a planned tandem or autologous-allogeneic transplant were excluded.Fifty-seven patients were treated with sAHCT2. Patients had a median of 2 lines of therapy after AHCT1 prior to their sAHCT2; 70% had prior immunomodulatory imide drugs, 82% had prior proteasome inhibitor, and 20% had prior anti-CD38 monoclonal antibodies as part of re-induction therapy. Forty-two percent of patients attained ≥VGPR prior to sAHCT2. Seventy-four were treated with melphalan 200 mg/mFor MM patients deriving durable remission after their AHCT1, sAHCT2 was safe and resulted in deep and durable remissions.
- Published
- 2022
3. Racial differences as predictors of outcomes in young patients with multiple myeloma
- Author
-
Alicia Bao, Qiuhong Zhao, Elizabeth Merritt, Naresh Bumma, Srinivas Devarakonda, Abdullah M. Khan, Elvira Umyarova, Ashley E. Rosko, Don M. Benson, and Francesca Cottini
- Subjects
Oncology ,Humans ,Health Status Disparities ,Hematology ,Healthcare Disparities ,Multiple Myeloma ,Race Factors - Published
- 2022
4. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- Author
-
Abdullah M. Khan, Filiz Yucebay, Qiuhong Zhao, Elvira Umyarova, Francesca Cottini, Naresh Bumma, Ashley Rosko, Don Benson, Nidhi Sharma, Yvonne Efebera, and Srinivas Devarakonda
- Subjects
Cancer Research ,Oncology ,Hematology - Abstract
High-dose melphalan (HDM) with autologous hematopoietic cell transplantation (AHCT) after induction chemotherapy is considered standard of care in transplant-eligible patients with newly-diagnosed multiple myeloma (MM). Alkeran melphalan has propylene glycol as a solvent (PG-mel) while Evomela utilizes a propylene glyclol-free formulation (PGF-mel). We evaluated the differences in efficacy and safety of the 2 formulations as there are no prospective head-to-head trials.We retrospectively reviewed the medical records of all 259 consecutive MM patients who received PGF-mel as part of HDM-AHCT at The Ohio State University (OSU). The comparator group was the preceding 255 patients who received PG-mel.Baseline patient characteristics were similar between the 2 groups. Post-AHCT rates of relapse were comparable in the PG-mel and PGF-mel groups. Some adverse events were observed at a higher frequency in the PG-mel group compared to the PGF-mel group (grade ≥ 2 mucositis, febrile neutropenia, other infectious complications, and acute renal insufficiency). Time to neutrophil engraftment was slightly longer in the PG-mel group while time to platelet engraftment was longer in PGF-mel group. Red cell transfusion requirement was higher with the use of PG-mel but not platelet transfusion. Duration of hospitalization was slightly shorter with PGF-mel but readmission rates within 30 days of discharge were higher.Considering possible confounding factors could possibly account for observed differences in some adverse events, the comparable treatment responses, and difference in cost of the 2 formulation, The OSU reverted to PG-mel as the preferred formulation for HDM-AHCT in MM.
- Published
- 2022
5. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
- Author
-
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, and Geoffrey Shouse
- Subjects
Cancer Research ,Clinical Trials and Observations ,Adenine ,Hematology ,Lymphoma, B-Cell, Marginal Zone ,Cohort Studies ,Pyrimidines ,Treatment Outcome ,Oncology ,Piperidines ,Humans ,Pyrazoles ,Neoplasm Recurrence, Local ,Molecular Biology - Abstract
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study and divided the study population into three groups: “ibrutinib responders”—patients who achieved complete or partial response (CR/PR) to ibrutinib; “stable disease (SD)”; and “primary progressors (PP)”—patients with progression of disease as their best response to ibrutinib. One hundred and nineteen patients met the eligibility criteria with 58%/17% ORR/CR, 29% with SD, and 13% with PP. The median PFS and OS were 29 and 71.4 months, respectively, with no difference in PFS or OS based on the ibrutinib line of therapy or type of therapy before ibrutinib. Patients with complex cytogenetics had an inferior PFS (HR = 3.08, 95% CI 1.23–7.67, p = 0.02), while those with both complex cytogenetics (HR = 3.00, 95% CI 1.03–8.68, p = 0.04) and PP (HR = 13.94, 95% CI 5.17–37.62, p p = 0.03). In this largest study to date evaluating outcomes of R/R MZL treated with ibrutinib, we show that patients with primary refractory disease and those with PP on ibrutinib are very high-risk subsets and need to be prioritized for experimental therapies.
- Published
- 2022
6. P-250: Predictive factors for outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience
- Author
-
Abdullah Khan, Muhammad Faisal, Qiuhong Zhao, Michael Ozga, Naresh Bumma, Francesca Cottini, Srinivas Devarakonda, Ashley Rosko, Elvira Umyarova, and Don Benson
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
7. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
- Author
-
Saad Z. Usmani, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Shaji Kumar, Ehsan Malek, Susan Bal, Saurabh Chhabra, Michaela Liedtke, Robert F. Cornell, Ankit Kansagra, Smith Giri, Luciano J. Costa, Yubin Kang, Kelly N. Godby, and Ravi Vij
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Treatment outcome ,MEDLINE ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Refractory Multiple Myeloma ,Hematology ,Middle Aged ,Class (biology) ,Progression-Free Survival ,Benchmarking ,Treatment Outcome ,Benchmark (computing) ,Female ,business ,Multiple Myeloma - Published
- 2021
8. SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA
- Author
-
Alexandra M. Donovan, Narendranath Epperla, Elizabeth Handorf, Frederick Lansigan, Jason B. Kaplan, Michael C. Churnetski, Kami J. Maddocks, Elvira Umyarova, J. K. Anderson, Andrew M. Evens, Catherine Diefenbach, David A. Bond, Mengjun Wang, Jonathan Cohen, Julie M. Vose, Marcus Messmer, Alexandra E. Kovach, S. Narayana Rao Gari, N.M. Reddy, Alina S. Gerrie, Veronika Bachanova, Andreas K. Klein, Reem Karmali, Martin Bast, Julio C. Chavez, Brian T. Hill, Timothy S. Fenske, Oscar Calzada, Kay M. Ristow, David J. Inwards, P. B. Caimi, Diego Villa, Shalin Kothari, Yazeed Sawalha, Jennifer E Amengual, Martha Glenn, Shaoying Li, Stefan K. Barta, Jennifer K. Lue, Amitkumar Mehta, James N. Gerson, N. Wagner-Johntson, J. Mederios, Francisco J. Hernandez-Ilizaliturri, Saurabh Rajguru, Bhaskar Kolla, Bijal D. Shah, and Daniel J. Landsburg
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,First relapse ,business.industry ,Internal medicine ,medicine ,Mantle cell lymphoma ,Hematology ,General Medicine ,medicine.disease ,business - Published
- 2021
9. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- Author
-
Michaela Liedtke, Amarendra K. Neppalli, Elizabeth McGehee, Ehsan Malek, Saad Z. Usmani, Robert F. Cornell, Swapna Narayana, Ankit Kansagra, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Arjun Lakshman, Ridhi Gupta, Barry Paul, Joshua Mansour, Zhubin Gahvari, Ujjawal H. Gandhi, William Varnado, Alyssa Barnstead, Saurabh Chhabra, Mark A. Fiala, Emma C. Scott, Megan Jagosky, Saranya Kodali, Ravi Vij, Yubin Kang, Kelly N. Godby, Luciano J. Costa, and Shaji Kumar
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Population ,Antibodies, Monoclonal, Humanized ,Article ,Cohort Studies ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Refractory ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Immunologic Factors ,Progression-free survival ,education ,Multiple myeloma ,Aged ,Aged, 80 and over ,Isatuximab ,education.field_of_study ,Membrane Glycoproteins ,business.industry ,Antibodies, Monoclonal ,Daratumumab ,Hematology ,Middle Aged ,medicine.disease ,ADP-ribosyl Cyclase 1 ,Carfilzomib ,Progression-Free Survival ,Regimen ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Female ,Immunotherapy ,Multiple Myeloma ,business ,Proteasome Inhibitors - Abstract
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T(0)) was 50.1 months. The median overall survival (OS) from T(0) for the entire cohort was 8.6 [95% C.I. 7.5–9.9] months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory (IMiD) agent and a proteasome inhibitor (PI) to 5.6 months for “penta-refractory” patients (refractory to CD38 MoAB, 2 PIs and 2 IMiDs). At least one subsequent treatment regimen was employed after T(0) in 249 (90%) patients. Overall response rate to first regimen after T(0) was 31% with median progression-free survival (PFS) and OS of 3.4 and 9.3 months, respectively. PFS was best achieved with combinations of carfilzomib and alkylator (median 5.7 months), and daratumumab and IMiD (median 4.5 months). Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.
- Published
- 2019
10. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
- Author
-
Kami J. Maddocks, Oscar Calzada, Brian T. Hill, Timothy F. Burns, Michael I. Wang, Julie M. Vose, Alexandra E. Kovach, Bhaskar Kolla, Andreas K. Klein, Bhargavi Pulluri, Alexandra M. Donovan, Frederick Lansigan, David J. Inwards, Jennifer K. Lue, Elizabeth Handorf, Martin Bast, Paolo Caimi, Jonathon B. Cohen, Jason B. Kaplan, Richard I. Fisher, Michael C. Churnetski, Timothy S. Fenske, Elvira Umyarova, Diego Villa, Parv Chapani, Veronika Bachanova, Yazeed Sawalha, David A. Bond, Julio C. Chavez, Martha Glenn, Shaoying Li, Marcus Messmer, Shalin Kothari, Alina S. Gerrie, Stefan K. Barta, L. Jeffrey Medeiros, Reem Karmali, Jennifer E Amengual, Amitkumar Mehta, Saurabh Rajguru, Nishitha Reddy, Andrew M. Evens, Swapna Narayana Rao Gari, Catherine Diefenbach, Nina D. Wagner-Johnston, James N. Gerson, Jennifer Kelly Anderson, Francisco J. Hernandez-Ilizaliturri, Bijal D. Shah, and Daniel J. Landsburg
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Lymphoma, Mantle-Cell ,Risk Assessment ,Transplantation, Autologous ,Young Adult ,Antineoplastic Agents, Immunological ,Cyclin D1 ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Progression-free survival ,Young adult ,Aged ,Retrospective Studies ,business.industry ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Induction chemotherapy ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Lymphoma ,Transplantation ,North America ,Female ,Rituximab ,Mantle cell lymphoma ,business ,medicine.drug - Abstract
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score–weighted (PSW) analysis were performed. RESULTS Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
- Published
- 2019
11. P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma
- Author
-
Ravi Vij, Shaji Kumar, Smith Giri, Saad Z. Usmani, Robert F. Cornell, Ankit Kansagra, Michaela Liedtke, Saurabh Chhabra, Luciano J. Costa, Yubin Kang, Kelly N. Godby, Susan Bal, Ehsan Malek, Natalie S. Callander, Elvira Umyarova, and Parameswaran Hari
- Subjects
Oncology ,Cancer Research ,Class (computer programming) ,medicine.medical_specialty ,business.industry ,Refractory Disease ,Hematology ,medicine.disease ,Clinical trial ,Internal medicine ,Relapsed refractory ,Benchmark (computing) ,Medicine ,business ,Multiple myeloma - Published
- 2021
12. Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>
- Author
-
Amarendra K. Neppalli, Sagar Lonial, Shaji Kumar, Sundar Jagannath, Jatin P. Shah, Mark A. Fiala, Paul G. Richardson, Joshua Mansour, Megan Jagosky, Ujjawal H. Gandhi, Zhubin Gahvari, Yubin Kang, Kelly N. Godby, Michaela Liedtke, Elizabeth McGehee, Ravi Vij, Xiwen Ma, David S. Siegel, Robert F. Cornell, Barry Paul, Ehsan Malek, William Varnado, Ankit Kansagra, Shijie Tang, Luciano J. Costa, Saad Z. Usmani, Emma C. Scott, Arjun Lakshman, Michael Kauffman, Noa Biran, Ridhi Gupta, Saurabh Chhabra, Saranya Kodali, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Sharon Shacham, and Ajai Chari
- Subjects
Oncology ,Disease free survival ,medicine.medical_specialty ,Standard of care ,business.industry ,Refractory Multiple Myeloma ,Hematology ,Clinical trial ,Multicenter study ,Internal medicine ,medicine ,Overall survival ,business ,Survival rate ,Dexamethasone ,medicine.drug - Published
- 2020
13. Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
- Author
-
Alexander Karabachev, Elvira Umyarova, Taimoor Jahangir, and Waqas Jehangir
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Azacitidine ,Decitabine ,Case Report ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Diseases of the blood and blood-forming organs ,Lenalidomide ,Venetoclax ,business.industry ,Myelodysplastic syndromes ,Myeloid leukemia ,General Medicine ,medicine.disease ,Transplantation ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,RC633-647.5 ,business ,medicine.drug - Abstract
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia. Currently, there are no curative FDA-approved medications for myelodysplastic syndromes. Hematopoietic cell transplantation is potentially the only curative option; however, treatment is often unavailable due to age and comorbidities. Hypomethylating agents, azacitidine and decitabine, and the immunomodulatory agent, lenalidomide, are the only FDA approved medications for the treatment of MDS, all of which are noncurative. Venetoclax, an inhibitor of the antiapoptotic protein BCL-2 used to treat chronic lymphocytic leukemia, is currently being evaluated in clinical trials as a monotherapy in high-risk myelodysplastic syndromes/acute myeloid leukemia. We present a patient with transfusion-dependent myelodysplastic syndromes refractory to the current standard of care treatment not a candidate for hematopoietic cell transplantation who responded well to monotherapy treatment with venetoclax and has since remained transfusion-independent.
- Published
- 2020
14. Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study
- Author
-
Cherie Tan, Lauren Shea, Yazeed Sawalha, Farrukh T. Awan, Geoffrey Shouse, Beth Christian, Tamara K. Moyo, Jonathon B. Cohen, Paolo Caimi, Qiuhong Zhao, Nishitha Reddy, Andrew R. Hsu, Murali Janakiram, Adam J. Olszewski, Joseph Maakaron, Natalie S Grover, Neil Palmisiano, Stefan K. Barta, Elvira Umyarova, Praveen Ramakrishnan Geethakumari, Kathryn G. Lindsey, Pallawi Torka, Alex F. Herrera, Kevin A. David, Celeste M. Bello, David M. Weiner, Ximena Jordan-Bruno, Narendranath Epperla, Nancy L. Bartlett, Michael C. Churnetski, Malathi Kandarpa, Sayan Mullick Chowdhury, Irl Brian Greenwell, Julia Sheets, Colin Thomas, and Ryan A. Wilcox
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Marginal zone lymphoma ,Cell Biology ,Hematology ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Ibrutinib ,Internal medicine ,Relapsed refractory ,Medicine ,business ,health care economics and organizations ,Cohort study - Abstract
Introduction Ibrutinib was FDA approved for relapsed or refractory (R/R) marginal zone lymphoma (MZL) based on a phase II clinical trial that showed an overall response rate of 48% (Noy et al, Blood 2017). However, factors associated with response to ibrutinib in R/R MZL and outcomes of patients after progression on ibrutinib are unknown. Given the poor survival in other B-cell lymphomas such as mantle cell lymphoma (MCL) after progression on ibrutinib (Martin P et al, Blood 2016), we sought to evaluate clinicopathologic characteristics predictive of ibrutinib failure in R/R MZL, and describe outcomes of patients who experienced progression on ibrutinib therapy. Methods We performed a multicenter retrospective study of MZL patients treated at 19 US medical centers. Eligible patients were ≥ 18 years diagnosed with MZL from 2010-2019, who received ibrutinib for R/R MZL. Patients achieving a complete response (CR) or partial response (PR) with ibrutinib were considered ibrutinib responders, while those who had stable disease (SD) or progression of disease (PD) were classified as non-responders. The primary endpoint was to evaluate factors predictive of primary progression (PD) on ibrutinib. Secondary endpoints include evaluation of predictors of overall survival (OS) and progression-free survival (PFS) following ibrutinib therapy, assessment of outcomes based on the sequencing of ibrutinib therapy, and evaluation of outcomes following ibrutinib failure. PFS was defined as time from the start of ibrutinib therapy until lymphoma relapse/progression or death from any cause, censoring at last clinical assessment if no progression or death. OS was defined as time from the start of ibrutinib treatment until death or last follow-up. A multivariable Poisson regression analysis was performed to model ibrutinib progression on the clinicopathologic factors (see Table). To identify significant predictors for OS and PFS, we used a multivariable Cox model. Results 101 patients with R/R MZL received ibrutinib, of whom 99 had sufficient data for inclusion in the analysis. Among these patients, 63% (n=62) had CR/PR to ibrutinib (ibrutinib responders, CR=17, PR=45) and 37% (n=37) had no response (ibrutinib non-responders, SD=25, PD=12). The median duration of follow-up was 1.8 years (range=0.1-5.4 years) and 2 years (range=0.2-6.3 years) for ibrutinib responders and non-responders, respectively. Baseline characteristics of the R/R MZL patients stratified by ibrutinib response are shown in the Table. Among all the baseline factors examined for association with ibrutinib progression, only primary refractory disease (refractory to frontline therapy, RR=3.78, 95%CI=1.36-10.45, p=0.01) was predictive of a higher probability of primary progression on ibrutinib on multivariable analysis. The median OS was significantly better for responders (NR [not reached], 95%CI=3.2-NR) compared to non-responders (3.4 years, 95%CI=1.4-NR) (Figure 1A). Achieving CR/PR with ibrutinib (HR=0.22, 95%CI=0.09-0.52) and lack of complex cytogenetics (HR=0.22, 95%CI=0.08-0.59) were predictors of superior PFS. Similarly, ibrutinib response (HR=0.13, 95%CI=0.03-0.53) and lack of complex cytogenetics (HR=0.19, 95%CI=0.04-0.87) were predictors of better OS. There was no difference in PFS or OS based on the timing of ibrutinib administration (second vs third vs fourth line and beyond, Figure 1B and 1C). The median post ibrutinib relapse/progression OS (PROS) for patients who initially responded then progressed on ibrutinib (secondary progression, n=19) was 4 years (Figure 1D). The median PROS for patients who had no response to ibrutinib were stratified according to SD vs PD. The median PROS for those who had SD was NR and those with PD was 0.1 year (Figure 1E). Conclusion This is the largest series of R/R MZL patients treated with ibrutinib. A history of primary refractory disease was predictive of primary progression on ibrutinib, while the presence of complex cytogenetics was associated with inferior PFS and OS. In contrast to MCL, the outcomes of patients who progress on ibrutinib in R/R MZL are not poor except for the primary progression cohort (those with PD as the best response to ibrutinib). Improving therapeutic options for patients who experience PD with ibrutinib treatment represents an urgent unmet need and these patients should be prioritized for evaluation of novel therapeutic approaches. Figure Disclosures Epperla: Verastem Oncology: Speakers Bureau; Pharmacyclics: Honoraria. Reddy:Genentech, BMS: Research Funding; KITE Pharma, Abbvie, BMS, Celgene: Consultancy. Caimi:Genentech: Research Funding; Celgene Corp: Other: Incyte Corporation - Ownership - Pharmacyclics, Inc. - Ownership - Celgene Corp. - Other, Speakers Bureau; ADC Therapeutics: Research Funding. Greenwell:Lymphoma Research Foundation: Research Funding; Acrotech Biopharma LLC, Kyowa Kirin: Consultancy. Janakiram:Takeda, Fate, Nektar: Research Funding. Olszewski:Genentech, Inc.: Research Funding; Spectrum Pharmaceuticals: Research Funding; TG Therapeutics: Research Funding; Adaptive Biotechnologies: Research Funding. Cohen:Genentech, BMS, Novartis, LAM, BioInvent, LRF, ASH, Astra Zeneca, Seattle Genetics: Research Funding; Janssen, Adicet, Astra Zeneca, Genentech, Aptitude Health, Cellectar, Kite/Gilead, Loxo: Consultancy. Palmisiano:AbbVie: Research Funding; Genentech: Research Funding. Awan:Genentech: Consultancy; Janssen: Consultancy; Astrazeneca: Consultancy; Abbvie: Consultancy; Pharmacyclics: Consultancy; Gilead Sciences: Consultancy; Kite Pharma: Consultancy; Dava Oncology: Consultancy; Celgene: Consultancy; Blueprint medicines: Consultancy; Sunesis: Consultancy; Karyopharm: Consultancy; MEI Pharma: Consultancy. Barta:Monsanto: Consultancy; Atara: Honoraria; Seattle Genetics: Honoraria, Research Funding; Janssen: Honoraria; Pfizer: Honoraria. Grover:Genentech: Research Funding; Tessa: Consultancy. Bartlett:Roche/Genentech: Consultancy, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Affimed Therapeutics: Research Funding; Acerta: Consultancy; BTG: Consultancy; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics: Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium: Research Funding; Merck: Research Funding; Forty Seven: Research Funding; Immune Design: Research Funding; Janssen: Research Funding; Kite, a Gilead Company: Research Funding; ADC Therapeutics: Consultancy; Autolus: Research Funding; BMS/Celgene: Research Funding. Christian:Acerta: Research Funding; Celgene: Research Funding; Genentech: Research Funding; Merck: Research Funding; Millenium: Research Funding; MorphoSys: Research Funding; F Hoffman-La Roche: Research Funding; Triphase: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Verastem: Membership on an entity's Board of Directors or advisory committees; AstraZenica: Membership on an entity's Board of Directors or advisory committees. Herrera:Pharmacyclics: Research Funding; Immune Design: Research Funding; AstraZeneca: Research Funding; Seattle Genetics: Consultancy, Research Funding; Gilead Sciences: Consultancy, Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Other: Travel, Accomodations, Expenses, Research Funding; Karyopharm: Consultancy.
- Published
- 2020
15. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional 'hits' and outcomes with subsequent therapy
- Author
-
Michael Jaglal, Nishitha Reddy, Luciano J. Costa, Narendranath Epperla, Jonathon B. Cohen, Mehdi Hamadani, Cristiana A Costa, Elvira Umyarova, Andrew J. Evans, Frederick Lansigan, Nasheed Hossain, Martha Glenn, Veronika Bachanova, Stefan K. Barta, Mohammed Salhab, Ana C. Xavier, Zheng Zhou, Francisco J. Hernandez-Ilizaliturri, Saurabh Chhabra, Reem Karmali, Christopher R. Flowers, Amitkumar Mehta, Julio C. Chavez, Kami J. Maddocks, Timothy S. Fenske, Zeina Al-Mansour, and Oscar Calzada
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hazard ratio ,Salvage therapy ,Cancer ,Retrospective cohort study ,medicine.disease ,Lymphoma ,Surgery ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Chemoimmunotherapy ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,medicine ,business ,030215 immunology - Abstract
BACKGROUND The impact of MYC proto-oncogene, basic helix-loop-helix (MYC) translocations (with or without additional rearrangements involving the B-cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B-cell lymphoma (DLBCL) who experience primary treatment failure is not well defined. METHODS This was a multicenter, retrospective study of the impact of MYC, BCL2, and BCL6 rearrangements in patients with DLBCL who failed to achieve complete remission or relapsed within 6 months after they completed upfront chemoimmunotherapy. RESULTS The authors examined response to salvage therapy, receipt of hematopoietic cell transplantation (HCT), and survival outcomes in MYC-negative (n = 120), MYC-positive single hit (SH) (n = 20), and MYC-positive double hit/triple hit (DH/TH) (n = 35) cohorts. The overall response rate in these cohorts to first salvage therapy (51%, 50%, and 54%, respectively) and receipt of HCT (52%, 40%, and 43%, respectively) were comparable between the 3 cohorts. The 2-year overall survival rate was 29.9% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 9.9% in the MYC-positive DH/TH cohort (P < .001), and no difference was observed between the SH and DH/TH cohorts (P = .8). The higher risk of death for patients with MYC-positive SH DLBCL (hazard ratio, 1.70; 95% confidence interval, 0.98-2.96; P = .06) and those with MYC-positive DH/TH DLBCL (hazard ratio, 2.22; 95% confidence interval, 1.41-3.50; P = .001) persisted after adjusting for covariates. For patients who underwent autologous HCT, the 2-year overall survival rate was 55.4% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 19.4% in the MYC-positive DH/TH cohort (P < .001). All 4 MYC-positive patients who underwent allogeneic HCT relapsed in
- Published
- 2017
16. Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
- Author
-
Mark A. Fiala, Saad Z. Usmani, Jatin J. Shah, Sundar Jagannath, Sagar Lonial, Shijie Tang, Saurabh Chhabra, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar, Arjun Lakshman, Robert F. Cornell, Paul G. Richardson, Noa Biran, Ehsan Malek, Ajai Chari, David S. Siegel, Michael Kauffman, Xiwen Ma, Amarendra K. Neppalli, Ujjawal H. Gandhi, Sharon Shacham, Natalie S. Callander, Elvira Umyarova, and Parameswaran Hari
- Subjects
Oncology ,medicine.medical_specialty ,Bortezomib ,business.industry ,Immunology ,Daratumumab ,Cell Biology ,Hematology ,Pomalidomide ,medicine.disease ,Biochemistry ,Carfilzomib ,chemistry.chemical_compound ,Refractory ,chemistry ,Internal medicine ,medicine ,business ,Dexamethasone ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Introduction: Proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and the CD38 monoclonal antibody daratumumab (dara) have transformed the management of MM, yet eventual refractoriness to these agents seems inevitable. Relapsed and refractory MM (RRMM) which becomes triple class refractory (TCR, i.e. refractory to a PI, an IMiD and Dara) uncommonly responds to further lines of therapy and survival is dismal. Selinexor is a selective inhibitor of nuclear export compound targeting exportin 1 (XPO1) which is overexpressed in MM cells and essential for their survival. In the STORM study, selinexor in combination with low-dose dexamethasone (Sd) demonstrated promising efficacy in TCR, penta-exposed (TCR-PE, i.e. exposed to lenalidomide, pomalidomide, bortezomib, carfilzomib and dara) MM. Establishing the natural history for outcomes in the TCR-PE population can help provide context to understand the outcomes observed with Sd in STORM. In the retrospective MAMMOTH study, we reported the outcomes of patients with RRMM after they became refractory to dara, including a subset of patients who were TCR. We further analyzed the MAMMOTH dataset to generate a cohort of patients similar to patients in STORM in order to compare conventional care vs. Sd. Methods: We included all patients in STORM who received Sd as the first line therapy after they achieved TCR-PE status (n=64). We extracted from the MAMMOTH dataset all patients who were not exposed to Sd in a subsequent line of therapy, became TCR-PE and who received subsequent MM-directed therapy (n=128). Overall response rate (ORR) was evaluated according to IMWG criteria. Overall survival (OS) was calculated from the time of initiation of next line of therapy after TCR-PE status until death or last follow-up. We compared OS in STORM vs. MAMMOTH utilizing cox-regression analysis with adjustment for covariables potentially influencing the outcome. Results: Baseline patient characteristics and prior therapies are per table. The two cohorts were similar in terms of age, number of prior lines of therapy and presence of high-risk cytogenetic abnormalities. STORM patients had longer time between MM diagnosis and post TCR-PE therapy with a higher proportion of refractoriness to carfilzomib. Patients in STORM had ORR to Sd of 32.8% vs 25.0% for patients receiving conventional care in MAMMOTH (P=0.078). In direct comparison, patients in STORM had better OS than patients in MAMMOTH (median 10.4 vs. 6.9 months) (P=0.043, figure). In multivariate analysis, STORM patients had lower risk of death in comparison with MAMMOTH patients (aHR=0.55, 95%C.I. 0.35-0.86, P=0.009). Refractoriness to carfilzomib (aHR=2.20, 95%C.I. 1.16-4.15, P=0.015) and high-risk cytogenetics (aHR-1.66, 95% C.I. 1.13-2.42, P=0.009) were also associated with inferior OS. Conclusion: Despite inherent limitations in comparison of trial enrollees vs. real world patients, this analysis suggests improved OS with Sd vs conventional care in patients with TCR-PE RRMM. Prognosis for these patients remains poor and underscores the need for therapeutic advancements. Disclosures Costa: Janssen: Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Speakers Bureau; GSK: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy; Karyopharm: Consultancy; Fujimoto Pharmaceutical Corporation Japan: Other: Advisor; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau. Hari:Kite: Consultancy, Honoraria; Amgen: Research Funding; Spectrum: Consultancy, Research Funding; Sanofi: Honoraria, Research Funding; Janssen: Consultancy, Honoraria; BMS: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Cell Vault: Equity Ownership; AbbVie: Consultancy, Honoraria. Kumar:Janssen: Consultancy, Research Funding; Takeda: Research Funding; Celgene: Consultancy, Research Funding. Tang:Karyopharm: Employment. Shah:Karyopharm Therapeutics Inc: Employment, Equity Ownership. Jagannath:BMS: Consultancy; Merck: Consultancy; Medicom: Speakers Bureau; Celgene: Consultancy; Novartis: Consultancy; Multiple Myeloma Research Foundation: Speakers Bureau. Chari:Oncoceutics: Research Funding; Novartis Pharmaceuticals: Research Funding; GlaxoSmithKline: Research Funding; Array Biopharma: Research Funding; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium/Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding. Shacham:Karyopharm Therapeutics Inc: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Ma:Karyopharm: Employment, Equity Ownership. Siegel:Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol-Myers Squibb Company: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Biran:Amgen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Bristol Meyers Squibb: Research Funding. Lonial:BMS: Consultancy; Genentech: Consultancy; GSK: Consultancy; Janssen: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Amgen: Consultancy; Celgene Corporation: Consultancy, Research Funding; Karyopharm: Consultancy. Richardson:Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Research Funding. Kauffman:Karyopharm Therapeutics Inc: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Malek:Adaptive: Consultancy; Amgen: Speakers Bureau; Janssen: Speakers Bureau; Celgene: Consultancy; Takeda: Consultancy; Sanofi: Consultancy; Medpacto: Research Funding. Fiala:Incyte: Research Funding. Usmani:Amgen, Celgene, Janssen, Sanofi, Takeda: Speakers Bureau; Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, SkylineDX, Takeda: Other: Consultant/Advisor; Amgen Array Biopharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, Takeda: Other: Research Grant. Kang:Takeda Oncology: Consultancy; InCyte Corportation: Research Funding. Cornell:Takeda: Consultancy; KaryoPharm: Consultancy.
- Published
- 2019
17. Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)
- Author
-
Amarendra K. Neppalli, Joshua Mansour, Alyssa Barnstead, Ravi Vij, Sharon Shacham, Ehsan Malek, William Varnado, Shijie Tang, Ajai Chari, Megan Jagosky, Xiwen Ma, Shaji Kumar, Saranya Kodali, Saad Z. Usmani, Swapna Narayana, Ridhi Gupta, Jatin P. Shah, Yubin Kang, Emma C. Scott, Kelly N. Godby, Robert F. Cornell, Paul G. Richardson, Ankit Kansagra, Noa Biran, Ujjawal H. Gandhi, Elizabeth McGehee, Sundar Jagannath, David S. Siegel, Natalie S. Callander, Elvira Umyarova, Sagar Lonial, Luciano J. Costa, Michael Kauffman, Zhubin Gahvari, Arjun Lakshman, Mark A. Fiala, Hari Parameswaran, Barry Paul, Saurabh Chhabra, and Michaela Liedtke
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hematology ,medicine.disease ,Class (biology) ,Clinical trial ,Refractory ,Internal medicine ,medicine ,business ,Multiple myeloma - Published
- 2019
18. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
- Author
-
Deniz Peker, Oscar Calzada, Jonathon B. Cohen, Martha Glenn, Nishitha Reddy, Saurabh Chhabra, Reem Karmali, Luciano J. Costa, Zheng Zhou, Stefan K. Barta, Andrew M. Evens, Hossain Nasheed, Michael Jaglal, Cristiana A Costa, Andreas Forero-Torres, Frederick Lansigan, Christopher R. Flowers, Mehdi Hamadani, Amitkumar Mehta, Elvira Umyarova, Kami J. Maddocks, Ana C. Xavier, Timothy S. Fenske, Zeina Al-Mansour, Francisco J. Hernandez-Ilizaliturri, Veronika Bachanova, Julio C. Chavez, and Narendranath Epperla
- Subjects
Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,medicine.medical_treatment ,Salvage therapy ,Hematopoietic stem cell transplantation ,Transplantation, Autologous ,Article ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Chemoimmunotherapy ,Recurrence ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Treatment Failure ,Aged ,Retrospective Studies ,Salvage Therapy ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Lymphoma ,Surgery ,Transplantation ,Clinical trial ,Benchmarking ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Disease Progression ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,business ,Diffuse large B-cell lymphoma ,030215 immunology ,medicine.drug - Abstract
The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse
- Published
- 2017
19. MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy
- Author
-
Martha Glenn, Mohamed Salhab, Francisco J. Hernandez-Ilizaliturri, Julio C. Chavez, Stefan K. Barta, Veronika Bachanova, Luciano J. Costa, Narendranath Epperla, Timothy S. Fenske, Christopher R. Flowers, Amitkumar Mehta, Mehdi Hamadani, Reem Karmali, Jonathon B. Cohen, Ana C. Xavier, Zheng Zhou, Kami J. Maddocks, Frederick Lansigan, Elvira Umyarova, and Nishitha Reddy
- Subjects
Cancer Research ,Poor prognosis ,Oncology ,Refractory ,business.industry ,hemic and lymphatic diseases ,Cancer research ,Medicine ,Chromosomal translocation ,Newly diagnosed ,business ,medicine.disease ,Diffuse large B-cell lymphoma - Abstract
7541 Background: Translocations involving MYC are a hallmark of poor prognosis among patients with newly diagnosed DLBCL. The impact of MYC translocations with or without additional “hits” involving BCL2 or BCL6 in response to salvage therapy and survival in R/R DLCBL is not well defined. Methods: We performed a multicenter retrospective study of 176 patients with R/R DLBCL failing to achieve CR or relapsing within 6 months after completion of upfront chemoimmunotherapy and for whom FISH information on MYC, BCL2 and BCL6 was available. The objectives were to examine the response to salvage therapy, utilization of hematopoietic cell transplantation (HCT) and survival outcomes in MYC- (n = 120), MYC+ single hit (SH, n = 28), and MYC+ double hit (DH, n = 36) R/R DLBCL. Results: Overall response rate to first salvage therapy and utilization of HCT was comparable between the 3 cohorts (Table). 2-year OS was 0% in MYC+ SH, 8.8% in MYC+ DH and 29.9% in MYC- cases (p = 0.001) without difference in OS between SH and DH (P = 0.8). The higher risk of death for MYC+ SH (HR 1.79, 95% C.I. 1.03-3.11, P = 0.03) and MYC+ DH (HR 1.93, 95% C.I. 1.23-3.00, P = 0.004) persisted after adjustment for covariates. For patients who underwent auto-HCT, 2-year OS was 0% in MYC+ SH, 29.3% in MYC+ DH and 55.4% in MYC- cases (p < 0.001) without significant difference between SH and DH (P = 0.8). All 4 MYC+patients who underwent allo-HCT relapsed in < 4 months. Conclusions: MYC+ R/R DLBCL have similar response to salvage therapy than the MYC- counterparts but dismal survival irrespective of additional “hits” and even if HCT can be performed. MYC+ R/R DLBCL represents an unmet medical need and should be prioritized for clinical trials with novel agents and innovative cellular therapies. [Table: see text]
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.